伊立替康联合替吉奥二线治疗晚期胃癌的临床观察

目的：观察伊立替康联合替吉奥二线治疗晚期胃癌的近期疗效和毒副反应。方法：27例晚期胃癌患者采用伊立替康270mg/ m2，静脉滴注，第1天；替吉奥60mg/ m2，分早、晚两次口服，第1-14天，21天为一个周期。结果：26例可评价疗效，其中 CR 1例，PR 8例，SD 8例，有效率34.6%，疾病控制率65.4%。常见毒副反应主要有恶心、呕吐、乏力、骨髓抑制、腹泻等，但多为 I/ II 度。结论：伊立替康联合替吉奥二线治疗晚期胃癌近期疗效较好，毒副反应可耐受。

Clinical study of irinotecan combined with S - 1 as second - line treatment for advanced gastric cancer

To observe the short - term effects and adverse reactions of irinotecan combined with S - 1 as secongd - line treatment for advanced gastric cancer. Methods：Irinotecan was administered iv（270mg/ m2 ）on day 1,while S - 1 was administered orally60mg/（m2 ·day）,bid]for 14 days followed by a 7 - day rest. This schedule was repeated every 3 weeks. Results：All 26 patients were evaluable,1 patient reached complete response（CR）,8 partial responses（PR）,8 stable disease. The overall response rate was 34. 6% ,disease control rate was 65. 4% . The major adverse effects were nausea and vomiting,fatigue,hematological,diarrhea. Conclusion：Irinotecan combined with S - 1 shows good efficacy as second - line in treatment for advanced gastric cancer. The quality of life can be im-proved and the toxicity is tolerable.